Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Br J Ophthalmol ; 93(10): 1359-64, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18977788

RESUMEN

AIM: To determine the carrier frequency of ABCA4 mutations in order to achieve an insight into the prevalence of autosomal recessive Stargardt disease (arSTGD) in the Spanish population. METHODS: arSTGD patients (n = 133) were analysed using ABCR400 microarray and sequencing. Control subjects were analysed by two different strategies: 200 individuals were screened for the p.Arg1129Leu mutation by denaturing-HPLC and sequencing; 78 individuals were tested for variants with the microarray and sequencing. RESULTS: For the first strategy in control subjects, the p.Arg1129Leu variant was found in two heterozygous individuals, which would mean a carrier frequency for any variant of approximately 6.0% and a calculated arSTGD prevalence of 1:1000. For the second strategy, carrier frequency was 6.4% and therefore an estimated prevalence of the disease of 1:870. CONCLUSION: Calculated prevalence of arSTGD based on the ABCA4 carrier frequency could be considerably higher than previous estimation. This discrepancy between observed (genotypic) and estimated (phenotypic) prevalence could be due to the existence of non-pathological or low penetrance alleles, which may result in late-onset arSTGD or may be implicated in age-related macular degeneration. This situation should be regarded with special care when genetic counselling is given and further follow-up of these patients should be recommended.


Asunto(s)
Transportadoras de Casetes de Unión a ATP/genética , Degeneración Macular/genética , Mutación , Estudios de Casos y Controles , Análisis Mutacional de ADN/métodos , Frecuencia de los Genes , Genes Recesivos , Genotipo , Heterocigoto , Humanos , Degeneración Macular/epidemiología , Prevalencia , España/epidemiología
2.
J Assist Reprod Genet ; 25(9-10): 477-81, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18853247

RESUMEN

PURPOSE: We focused on the improvements of prenatal diagnosis by the analysis of DNA from maternal plasma, using Huntington disease as a model of disease. METHODS: We studied plasma from a pregnancy at risk of having a fetus affected with Huntington disease by the use of two direct analysis of the mutation and polymorphic STRs. RESULTS: Direct methods were not informative. Analysis with STRs revealed the presence of the allele that does not co-segregate with the disease, thus the fetus was healthy. CONCLUSIONS: This strategy is very useful to face complex cases when the direct study is not informative not only for Huntington disease but also for many other disorders.


Asunto(s)
ADN/sangre , Enfermedad de Huntington/diagnóstico , Diagnóstico Prenatal , ADN/genética , Femenino , Humanos , Enfermedad de Huntington/genética , Masculino , Repeticiones de Microsatélite , Mutación , Embarazo
3.
Ann N Y Acad Sci ; 1075: 108-17, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17108199

RESUMEN

The discovery of circulating fetal DNA in maternal blood has been an encouraging step forward in the prenatal diagnostic field. It has opened up the possibility of development of a noninvasive method for the genetic analysis of the fetus. Many techniques have been applied to the study of this fetal DNA, but automated sequencing has been seldom used. The intention of this study was to use the automated sequencing technique for the detection of a paternally inherited fetal mutation in maternal plasma. Maternal plasma samples from a pregnant woman, whose husband had a mutation (Q134X) in the RP2 gene, which is located in the X-chromosome, were collected at two different gestational ages (10th and 19th week of gestation) in order to determine whether the paternally inherited fetal mutation could be detected by automated sequencing. Restriction analysis was also performed to confirm the results. The fetal mutation was clearly detected in the maternal plasma by the use of automated sequencing. The automated sequencing enables the possibility of analyzing fetal sequences, at a nucleotide level, in order to detect mutations or polymorphisms which are distinguishable from maternal sequences.


Asunto(s)
ADN/sangre , Proteínas del Ojo/genética , Padre , Feto/fisiología , Péptidos y Proteínas de Señalización Intracelular/genética , Proteínas de la Membrana/genética , Mutación Puntual , Diagnóstico Prenatal/métodos , Secuencia de Bases , Cromosomas Humanos X/genética , Análisis Mutacional de ADN , Femenino , Proteínas de Unión al GTP , Edad Gestacional , Humanos , Datos de Secuencia Molecular , Linaje , Reacción en Cadena de la Polimerasa , Embarazo , Retinitis Pigmentosa/diagnóstico , Retinitis Pigmentosa/genética
4.
J Histochem Cytochem ; 53(3): 307-14, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15750008

RESUMEN

Non-invasive prenatal diagnosis tests based on the analysis of fetal DNA in maternal plasma have potential to be a safer alternative to invasive methods. So far, different studies have shown mainly fetal sex, fetal RhD, and quantitative variations of fetal DNA during gestation with fetal chromosomal anomalies or gestations at risk for preeclampsia. The objective of our research was to evaluate the use of fetal DNA in maternal plasma for clinical application. In our study, we have established the methodology needed for the analysis of fetal DNA. Different methods were used, according to the requirements of the assay. We have used quantitative fluorescent polymerase chain reaction (QF-PCR) to perform fetal sex detection with 90% sensitivity. The same technique permitted the detection of fetal DNA from the 10th week of gestation to hours after delivery. We have successfully carried out the diagnosis of two inherited disorders, cystic fibrosis (conventional PCR and restriction analysis) and Huntington disease (QF-PCR). Ninety percent of the cases studied for fetal RhD by real-time PCR were correctly diagnosed. The detection of fetal DNA sequences is a reality and could reduce the risk of invasive techniques for certain fetal disorders in the near future.


Asunto(s)
ADN/sangre , Enfermedades Fetales/diagnóstico , Feto , Diagnóstico Prenatal , Fibrosis Quística/diagnóstico , Fibrosis Quística/genética , Femenino , Enfermedades Fetales/genética , Fluorescencia , Humanos , Enfermedad de Huntington/diagnóstico , Enfermedad de Huntington/genética , Mutación , Reacción en Cadena de la Polimerasa , Embarazo , Sistema del Grupo Sanguíneo Rh-Hr/genética , Análisis para Determinación del Sexo/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA